| Royalty Pharma to Present at Upcoming Investor Conferences |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: |
globenewswire.com |
2025-05-13 12:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition |
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company. |
globenewswire.com |
2025-05-12 20:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma: Again, Guidance Raised, Buy Confirmed |
Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, with a 2.6% dividend yield. |
seekingalpha.com |
2025-05-12 01:18:53 |
Czytaj oryginał (ang.) |
| Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript |
Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and Vice Chairman Conference Call Participants Hardik Parikh - JPMorgan Mike Nedelcovych - TD Cowen Terence Flynn - Morgan Stanley Geoff Meacham - Citi Jason Gerberry - Bank of America Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call. |
seekingalpha.com |
2025-05-08 16:44:58 |
Czytaj oryginał (ang.) |
| Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-08 15:30:41 |
Czytaj oryginał (ang.) |
| Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates |
Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago. |
zacks.com |
2025-05-08 13:30:53 |
Czytaj oryginał (ang.) |
| Royalty Pharma Reports First Quarter 2025 Results |
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. |
globenewswire.com |
2025-05-08 11:15:00 |
Czytaj oryginał (ang.) |
| Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. |
zacks.com |
2025-05-05 14:21:09 |
Czytaj oryginał (ang.) |
| Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:06:27 |
Czytaj oryginał (ang.) |
| Royalty Pharma Declares Second Quarter 2025 Dividend |
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. |
globenewswire.com |
2025-04-21 20:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 |
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. |
globenewswire.com |
2025-04-17 20:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors |
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. |
globenewswire.com |
2025-04-08 20:15:00 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks With Massive Gains—and More to Come |
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far. |
marketbeat.com |
2025-03-29 09:16:26 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Upcoming Investor Day |
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. |
globenewswire.com |
2025-03-27 10:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma's “Events” page at https://www.royaltypharma.com/investors/events/. |
globenewswire.com |
2025-02-27 18:15:00 |
Czytaj oryginał (ang.) |
| 17 Upcoming Dividend Increases, Including 3 Kings |
This week's dividend increases feature three Dividend Kings: Archer-Daniels-Midland, Consolidated Edison, and Black Hills Corporation, with streaks of 50, 51, and 55 years, respectively. Consistently rising dividends indicate strong cash flow and financial stability, making such companies attractive long-term investments that often outperform benchmarks. My strategy focuses on stocks with consistent dividend growth and market outperformance, using data from U.S. Dividend Champions and NASDAQ. |
seekingalpha.com |
2025-02-13 13:03:22 |
Czytaj oryginał (ang.) |
| Royalty Pharma: Delivering Growth With A Positive Story Ahead |
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). |
seekingalpha.com |
2025-02-13 00:02:03 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces R&D Funding Collaboration With Biogen |
Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus |
globenewswire.com |
2025-02-12 08:30:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript |
Royalty Pharma plc (NASDAQ:RPRX ) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citi Christopher Schott - JPMorgan Chase & Co Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Dina Ramadane - Bank of America Securities. Ashwani Verma - UBS Operator Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference. |
seekingalpha.com |
2025-02-11 15:40:39 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings |
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-11 12:31:23 |
Czytaj oryginał (ang.) |
| Royalty Pharma Reports Q4 and Full Year 2024 Results |
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts. |
globenewswire.com |
2025-02-11 09:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds |
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive return by monetizing these future fixed payments at a low discount rate of 5.35% and will redeploy these proceeds into higher returning investment opportunities, including repurchasing its shares and acquiring attractive new royalties. |
globenewswire.com |
2025-01-29 11:00:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 |
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. |
globenewswire.com |
2025-01-28 18:15:00 |
Czytaj oryginał (ang.) |
| 4 Stocks With Growth Potential That Recently Announced Dividend Hikes |
PLBC, BUSE, LKFN and RPRX recently announced dividend hikes. |
zacks.com |
2025-01-22 11:50:34 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know |
The mean of analysts' price targets for Royalty Pharma (RPRX) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-20 12:55:14 |
Czytaj oryginał (ang.) |
| Royalty Pharma: Key Strategic Updates To Be Priced In |
Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. |
seekingalpha.com |
2025-01-15 05:49:27 |
Czytaj oryginał (ang.) |
| Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors |
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesting a long-term bullish trend. |
zacks.com |
2025-01-13 12:30:42 |
Czytaj oryginał (ang.) |
| Royalty Pharma simplifies corporate structure with $1.1 bln deal |
Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure. |
reuters.com |
2025-01-10 09:31:57 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held at 6:45 p.m. Eastern Time / 3:45 p.m. Pacific Time at the 43rd Annual J.P. Morgan Healthcare Conference. |
globenewswire.com |
2025-01-10 09:30:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program |
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years Simplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intended to be repurchased in 2025 subject to market conditions Maintain significant capacity for new royalty transactions and remain committed to mid-single digit percentage annual dividend growth and investment grade credit rating Royalty Pharma to host investor call today, Friday, January 10, 2025 at 8:30am ET NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value. First, the Board of Directors has agreed to acquire its external manager, RP Management, LLC (the “Manager”). |
globenewswire.com |
2025-01-10 09:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Dividend Increase |
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend. |
globenewswire.com |
2025-01-09 18:15:00 |
Czytaj oryginał (ang.) |
| ChatGPT picks 5 stocks to buy for the start of 2025 |
As we enter the tail end of 2024, which has been a great year for the markets, as the S&P 500 has rallied by 27.35% since the beginning of the year, one question lies on the minds of investors the world over — what do I invest in for next year? |
finbold.com |
2024-12-25 07:00:00 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer |
The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally. Royalty Pharma (RPRX 0.04%), W.P. |
fool.com |
2024-12-13 06:30:00 |
Czytaj oryginał (ang.) |
| 2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips |
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking at their stock prices. |
fool.com |
2024-12-04 07:37:00 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer |
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher. |
fool.com |
2024-12-03 06:24:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Present at Upcoming Investor Conferences |
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: |
globenewswire.com |
2024-11-27 18:15:00 |
Czytaj oryginał (ang.) |
| Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + |
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid- or high-teens per share. Casey's General Stores has outperformed its peers and the S&P 500 due to its strategic positioning in rural areas and strong operational execution. |
seekingalpha.com |
2024-11-16 10:00:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma Announces Inaugural Prize for Impact in Healthcare |
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient's work. |
globenewswire.com |
2024-11-14 18:30:00 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade |
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade |
fool.com |
2024-11-14 07:20:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma: Massive Opportunity Ahead |
Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. |
seekingalpha.com |
2024-11-09 02:46:39 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million |
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (Nasdaq: GERN) RYTELO for $125 million in cash upfront. |
globenewswire.com |
2024-11-07 09:10:00 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics |
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 20:01:30 |
Czytaj oryginał (ang.) |
| Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript |
Royalty Pharma plc (NASDAQ:RPRX ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Chris Hite - EVP, Vice Chairman Terry Coyne - EVP & CFO Conference Call Participants Hardik Parikh - JPMorgan Geoff Meacham - Citi Michael DiFiore - Evercore Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Ash Verma - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter Earnings Conference Call. |
seekingalpha.com |
2024-11-06 14:28:04 |
Czytaj oryginał (ang.) |
| Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates |
Royalty Pharma (RPRX) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago. |
zacks.com |
2024-11-06 11:35:37 |
Czytaj oryginał (ang.) |
| Royalty Pharma Reports Third Quarter 2024 Results |
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. |
globenewswire.com |
2024-11-06 09:15:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo |
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo (axatilimab-csfr). |
globenewswire.com |
2024-11-04 18:15:00 |
Czytaj oryginał (ang.) |
| Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ |
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Company through profitability; proforma cash approaching $800 million as of June 30 WALTHAM, Mass. and NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axatilimab-csfr). |
prnewswire.com |
2024-11-04 18:01:00 |
Czytaj oryginał (ang.) |
| Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. |
zacks.com |
2024-11-01 12:20:40 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Finance Stocks Now |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2024-10-21 13:55:21 |
Czytaj oryginał (ang.) |
| 3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income |
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire. |
fool.com |
2024-10-20 10:24:00 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 |
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. |
globenewswire.com |
2024-10-16 20:15:00 |
Czytaj oryginał (ang.) |